Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic TumorsReport as inadecuate




Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors - Download this document for free, or read online. Document in PDF available to download.

Treatments for retinoblastoma Rb vary depending on the size and location of the intraocular lesions and include chemotherapy and radiation therapy. We examined whether agents used to treat Rb induce a pro-survival phenotype associated with increased expression of survivin, a member of the inhibitor of apoptosis family of proteins. We document that exposure to carboplatin, topotecan or radiation resulted in elevated expression of survivin in two human Rb cell lines but not in normal retinal pigmented epithelial RPE cells. Cellular levels of survivin were attenuated in Rb cells exposed to an imidazolium-based survivin suppressant, Sepantronium bromide YM155. Protein expression patterns of survivin in RPE cells were not altered following treatment protocols involving exposure to YM155. Including YM155 with chemotherapy or radiation increased levels of apoptosis in Rb cells but not in RPE cells. Intraocular luciferase expressing Rb tumors were generated from the Rb cell lines and used to evaluate the effects of carboplatin and YM155 on in-vivo survivin expression and tumor growth. Carboplatin induced expression of survivin while carboplatin combined with YM155 reduced survivin expression in tumor bearing eyes. The combination protocol was also most effective in reducing the rate of tumor regrowth. These results indicate that targeted inhibition of the anti-apoptotic protein survivin provides a therapeutic advantage for Rb cells and tumors treated with chemotherapy.



Author: Angela Ferrario , Marian Luna , Natalie Rucker, Sam Wong, Ariel Lederman, Jonathan Kim, Charles Gomer

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents